NICE have published a guidance for Pfizer’s Xalkori drug to treat ROS1-postivie non-small cell lung cancer has been made available via the Cancer drugs fund.
Previously submitted in January this, year, the appraisal committee could see the promises that the treatment had to offer, but limited data at this time made it uncertain on the cost effectiveness. A confidential discounted price was agreed with NHS England and Pfizer whilst further data was gathered. Data collection will take place for five years and will be reviewed on an annual basis.
“Pfizer’s Xalkori drug to treat ROS1-postivie non-small cell lung cancer has been made available via the Cancer drugs fund. “
Head of Oncology at Pfizer UK Craig Eagle commented on the news, “The decision to make the drug available is good news for patients in England. We are committed to continuing to work in collaboration withal parties towards a long term solution on how to assess the limited data that’s’ available, and ensure timely routine access to modern cancer medicines now and in the future. ”